DNM1抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Mouse brain tissue, Primary antibody: P10820(DNM1 Antibody) at dilution 1/700, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 30 seconds    

  
  

The DNM1 antibody is associated with autoimmune neurological disorders, particularly autoimmune encephalitis. Dynamin 1 (DNM1), encoded by the *DNM1* gene, is a GTPase critical for synaptic vesicle endocytosis, facilitating neurotransmitter release and maintaining synaptic plasticity. Antibodies targeting DNM1 are rare but implicated in disrupting synaptic transmission, leading to neurological dysfunction.

First identified in patients with encephalitis, DNM1 antibodies are often detected alongside other neural autoantibodies (e.g., GAD65), complicating clinical characterization. Patients may present with seizures, cognitive decline, movement disorders, or psychiatric symptoms. DNM1 autoimmunity is occasionally linked to paraneoplastic syndromes, though many cases are idiopathic.

Diagnosis involves detecting antibodies in serum or cerebrospinal fluid (CSF) using cell-based assays (CBA) or immunohistochemistry. DNM1 antibody encephalitis often responds to immunotherapy (steroids, IVIG, or rituximab), though outcomes vary based on disease progression and comorbidities. Research on DNM1 antibodies remains limited, emphasizing the need for further studies to clarify their pathogenic mechanisms and clinical significance in autoimmune neurology.